1.Indications and outcomes of inferior vena cava filter insertion in a tertiary hospital in Metro Manila, Philippines: A retrospective cohort study.
Ma. Krizia Camille Yap-Uy ; Lester Uy ; Ramayana Diaz-Garcia
Philippine Journal of Cardiology 2023;51(2):35-43
INTRODUCTION
Inferior vena cava (IVC) filters entrap emboli from the periphery going to the pulmonary circulation, preventing pulmonary embolism (PE). Studies show that many IVC filter insertions are done for weak or non–guideline directed indications. This study examined the indications for IVC filter insertion in a tertiary care hospital in Metro Manila, adherence to society guidelines, and clinical outcomes after filter insertion.
METHODSThis study is a retrospective cohort involving patients who received an IVC filter from January 2015 to February 2021. The main outcome was the indication for IVC filter. Other outcomes were strength of recommendation for filter placement and postfilter clinical outcomes: all-cause death, venous thromboembolism–related mortality, PE, and filter related complications.
RESULTSEighty-three patients received IVC filters from January 2015 to February 2021, and 77 were included in the analysis. Sixty-one percent had moderate to strong indications for the procedure, 49% were due to contraindication to anticoagulation. Thirty-nine percent had unclear indications: 16% concomitantly received therapeutic anticoagulation, whereas 11% had isolated distal deep vein thrombosis. Mean follow-up was 170 days. Postfilter clinical outcomes included all-cause death in 12%, venous thromboembolism–related mortality in 1%, and PE in 3%. Filter complications occurred in 4%. Retrievable IVC filters were used in 51% with attempted removal in 4%, 3% of which were successful.
CONCLUSIONThe majority of patients receiving IVC filters in our center had strong to moderate indications for the procedure. The use of retrievable filters and consequent retrieval is low and should be encouraged. Venous thromboembolism–related mortality and filter complications were low, comparable to international data.
Echocardiography ; Laboratories ; Resources ; Surveys And Questionnaires
2.2023 Philippine Working Group Consensus Statement on renal denervation therapy for the management of hypertension
Raymond Oliva ; Deborah Ignacia D. Ona ; Lourdes Ella G. Santos ; Felix Eduardo Punzalan ; John David Tan ; Gilbert Villela ; Benjamin Balmores ; Krizia Camille Yap-Uy ; Roberta Maria Cawed-Mende ; Jose Nicholas Cruz
Philippine Journal of Cardiology 2024;52(1):12-18
BACKGROUND
Hypertension is the most common risk factor for cardiovascular disease in the Philippines. Despite the availability of antihypertensive medications that are effective, safe, and tolerated by Filipino patients, the numbers of uncontrolled hypertensives are still increasing. Several factors play in the poor control of blood pressure, particularly resistant hypertension and hyperactive sympathetic nervous system. Renal denervation therapy is a novel device that has been shown to lower blood pressure in patients with resistant and difficult-to-treat hypertension and is deemed safe in clinical trials. A Philippine Working Group composed of specialists in cardiology, hypertension, vascular surgery, and clinical epidemiology has come up with consensus statements in identifying patients who will benefit from the procedure. Locally, there is a need to have hypertension centers treating uncontrolled and resistant hypertension and offer renal denervation therapy to appropriate Filipino patients.
Blood Pressure